Highlights
- ResMed Inc. trades at $32.130, down 0.46% in the latest session despite strong quarterly earnings growth
- Q2 FY26 revenue rose 11% to $1.42 billion, with margin expansion and double-digit EPS growth
- Consensus “Buy” rating with a target price of AUD 47.09, reflecting strong long-term investor confidence
ResMed Inc. (ASX:RMD) is a global leader in sleep and respiratory care, operating at the intersection of medical devices and digital health technology. The company has built a strong reputation for innovation in treating sleep apnea and chronic respiratory conditions, supported by a rapidly expanding digital ecosystem.
At a current share price of $32.130, ResMed recorded a…
